Finding molecular
biomarkers that can be related to the degree of
cognitive dysfunction in
schizophrenia remains a challenge. The levels of 6
Serum Protein Factors (
NGF,
BDNF, IL-6, TNF-α, S100β, GFAP) in peripheral blood of patients with
schizophrenia were measured. The cognitive function of patients with
schizophrenia was assessed by MATRICS Consensus Cognitive Battery (MCCB), a systematic assessment tool of international gold standard for cognitive function assessment of
schizophrenia. To explore the correlation between these 6
biomarkers and the degree of
cognitive dysfunction in
schizophrenia,78 schizophrenic patients and 71 healthy controls were included in the study. The serum concentrations of
BDNF and GFAP were lower in the patient group, but the concentrations of
IL-6, TNF-α and S100β were higher. The speed of information processing, word learning, reasoning and problem solving, visual learning T-score of the patient group were lower than the control group. Bayes discriminant function model has a high correct discriminant rate for the severity of
cognitive dysfunction in
schizophrenia. The level of
serum protein factor and clinical symptom score of
schizophrenia may forecast the degree of
cognitive dysfunction, which is expected to be a potential
biomarker to identify the degree of
cognitive dysfunction of
schizophrenia, and provide objective basis for the clinical diagnosis and treatment of patients with
schizophrenia.